Teguh Hari Sucipto, .- and Siti Churrotin, .- and Harsasi Setyawati, .- and Fahimah Martak, .- and Kris Cahyo Mulyatno, .- and Ilham Harlan Amarullah, .- and Tomohiro Kotaki, .- and Masanori Kameoka, .- and Subagyo Yotopranoto, .- and Soegeng Soegijanto, .- (2018) A new copper (II)-imidazole derivative effectively inhibits replication of denv-2 in vero cell. African Journal of Infectious Diseases, 12 (1). pp. 116-119. ISSN 20060165

	Text (Fulltext) C14. Fulltext_r.pdf Download (921kB)
	Text (Penilaian dan Validasi) C14. Penilaian dan Validasi.pdf Download (739kB)
	Text (Simillarity) C14. Similarity.pdf Download (1MB)

Abstract

Background: Dengue is a kind of infectious disease that was distributed in the tropical and sub-tropical areas. To date, there is no clinically approved dengue vaccine or antiviral for humans, even though there have been great efforts towards this end. Therefore, finding the effective compound against dengue virus (DENV) replication is very important. Among the complex compounds, copper(II)-imidazole derivatives are of interest because of their biological and medicinal benefits. Materials and Methods: In the present study, antiviral activity of [Cu(2,4,5-triphenylimidazole) 2]n, was evaluated against different stages of dengue virus type 2 (DENV-2) replication in Vero cell using focus forming unit reduction assay and quantitative ELISA. Results: [Cu(2,4,5-triphenylimidazole) 2]n inhibited DENV-2 replication in Vero cells with IC 50 = 2.3 μg/ml and SI= 19.42 when cells were treated 2 days after virus infection, whereas its CC 50 for cytotoxicity to Vero cells was 44.174 μg/ml. Conclusion: The compound has high anti-DENV2 activity, less toxicity, and a high possibility to be considered a drug candidate.

Actions (login required)

View Item